• Clovis Oncology Inc., of Boulder, Colo., set terms for its proposed initial public offering. The company plans to sell 9.3 million shares priced between $13 and $15 apiece, the midpoint of which would raise $130.2 million. An additional 1.4 million shares will be available to underwriters J.P. Morgan, Credit Suisse and Leerink Swann to cover overallotments. The majority of proceeds will support its pipeline of cancer drugs. Clovis applied to list its common stock on the NASDAQ Global Market under the symbol "CLVS." (See BioWorld Today, June 24, 2011.)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST